Q9QZM4
SS
Gene name |
Tnfrsf10b (Dr5, Killer) |
Protein name |
Tumor necrosis factor receptor superfamily member 10B |
Names |
Death receptor 5 , MK , CD antigen CD262 |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:21933 |
EC number |
|
Protein Class |
|
Descriptions
Death receptor-5 (DR5) belongs to the tumor necrosis factor alpha (TNF-alpha) superfamily, contains three external cysteine-rich domain (CRD1-CRD3), and activates apoptotic signaling outside of cells. The negative regulatory function of a critical patch of positively charged residues (PPCR) within the CRD3 domain of DR3 is disrupted by sustained antibody binding, resulting in highly effective clustering of DR5 and apoptotic clustering to tumors.
Autoinhibitory domains (AIDs)
Target domain |
262-356 (Death domain) |
Relief mechanism |
Ligand binding |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q9QZM4
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q9QZM4-F1 | Predicted | AlphaFoldDB |
49 variants for Q9QZM4
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3389343430 | 9 | P>S | No | EVA | |
| rs13482239 | 42 | V>M | No | EVA | |
| rs3389351566 | 57 | N>K | No | EVA | |
| rs217962841 | 63 | Q>K | No | EVA | |
| rs3389336046 | 77 | G>V | No | EVA | |
| rs3389338362 | 93 | D>N | No | EVA | |
| rs3389351513 | 96 | S>N | No | EVA | |
| rs46978773 | 97 | H>Q | No | EVA | |
| rs48182953 | 97 | H>R | No | EVA | |
| rs221936633 | 97 | H>Y | No | EVA | |
| rs230815125 | 98 | S>P | No | EVA | |
| rs50177800 | 116 | V>F | No | EVA | |
| rs230466904 | 117 | V>I | No | EVA | |
| rs49024348 | 118 | E>K | No | EVA | |
| rs3389340816 | 127 | T>M | No | EVA | |
| rs46806096 | 128 | V>E | No | EVA | |
| rs3389293594 | 132 | K>* | No | EVA | |
| rs3389338351 | 134 | G>S | No | EVA | |
| rs3389343439 | 150 | N>K | No | EVA | |
| rs3389323698 | 150 | N>Y | No | EVA | |
| rs3389340831 | 152 | T>N | No | EVA | |
| rs236207563 | 156 | E>D | No | EVA | |
| rs263348475 | 158 | L>V | No | EVA | |
| rs579858227 | 160 | S>P | No | EVA | |
| rs586088378 | 164 | R>G | No | EVA | |
| rs580338398 | 164 | R>K | No | EVA | |
| rs3389346014 | 165 | E>* | No | EVA | |
| rs220994254 | 173 | T>K | No | EVA | |
| rs236298362 | 180 | K>N | No | EVA | |
| rs254200660 | 187 | L>P | No | EVA | |
| rs222860296 | 190 | P>A | No | EVA | |
| rs245196626 | 191 | V>A | No | EVA | |
| rs3508056631 | 199 | L>F | No | EVA | |
| rs583674807 | 212 | C>Y | No | EVA | |
| rs587531228 | 213 | I>M | No | EVA | |
| rs3389351546 | 215 | R>G | No | EVA | |
| rs30202691 | 229 | S>L | No | EVA | |
| rs3389338283 | 250 | G>S | No | EVA | |
| rs3389351509 | 264 | N>I | No | EVA | |
| rs3389336328 | 277 | E>D | No | EVA | |
| rs3389346071 | 278 | Y>F | No | EVA | |
| rs3389311410 | 286 | D>H | No | EVA | |
| rs30553025 | 306 | K>R | No | EVA | |
| rs219803432 | 310 | L>R | No | EVA | |
| rs243739566 | 311 | V>G | No | EVA | |
| rs264975360 | 316 | L>Q | No | EVA | |
| rs221428189 | 322 | K>R | No | EVA | |
| rs3389330008 | 328 | G>R | No | EVA | |
| rs37739936 | 360 | G>R | No | EVA |
No associated diseases with Q9QZM4
10 regional properties for Q9QZM4
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Oxidoreductase FAD/NAD(P)-binding | 213 - 327 | IPR001433 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 116 - 126 | IPR001709-1 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 139 - 146 | IPR001709-2 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 176 - 185 | IPR001709-3 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 212 - 231 | IPR001709-4 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 242 - 251 | IPR001709-5 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 254 - 265 | IPR001709-6 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 290 - 306 | IPR001709-7 |
| domain | Flavoprotein pyridine nucleotide cytochrome reductase | 314 - 322 | IPR001709-8 |
| domain | FAD-binding domain, ferredoxin reductase-type | 81 - 203 | IPR017927 |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| cell surface | The external part of the cell wall and/or plasma membrane. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
1 GO annotations of molecular function
| Name | Definition |
|---|---|
| TRAIL binding | Binding to TRAIL (TNF-related apoptosis inducing ligand), a member of the tumor necrosis factor ligand family that rapidly induces apoptosis in a variety of transformed cell lines. |
6 GO annotations of biological process
| Name | Definition |
|---|---|
| extrinsic apoptotic signaling pathway via death domain receptors | The series of molecular signals in which a signal is conveyed from the cell surface to trigger the apoptotic death of a cell. The pathway starts with a ligand binding to a death domain receptor on the cell surface, and ends when the execution phase of apoptosis is triggered. |
| intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | The series of molecular signals in which an intracellular signal is conveyed to trigger the apoptotic death of a cell. The pathway is induced in response to a stimulus indicating endoplasmic reticulum (ER) stress, and ends when the execution phase of apoptosis is triggered. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen. |
| negative regulation of multicellular organismal process | Any process that stops, prevents, or reduces the frequency, rate or extent of an organismal process, the processes pertinent to the function of an organism above the cellular level; includes the integrated processes of tissues and organs. |
| positive regulation of apoptotic process | Any process that activates or increases the frequency, rate or extent of cell death by apoptotic process. |
| response to endoplasmic reticulum stress | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen. |
| TRAIL-activated apoptotic signaling pathway | An extrinsic apoptotic signaling pathway initiated by the binding of the ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) to a death receptor on the cell surface. |
4 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| O00220 | TNFRSF10A | Tumor necrosis factor receptor superfamily member 10A | Homo sapiens (Human) | SS |
| O14798 | TNFRSF10C | Tumor necrosis factor receptor superfamily member 10C | Homo sapiens (Human) | PR |
| Q9UBN6 | TNFRSF10D | Tumor necrosis factor receptor superfamily member 10D | Homo sapiens (Human) | PR |
| O14763 | TNFRSF10B | Tumor necrosis factor receptor superfamily member 10B | Homo sapiens (Human) | EV |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MEPPGPSTPT | ASAAARADHY | TPGLRPLPKR | RLLYSFALLL | AVLQAVFVPV | TANPAHNRPA |
| 70 | 80 | 90 | 100 | 110 | 120 |
| GLQRPEESPS | RGPCLAGQYL | SEGNCKPCRE | GIDYTSHSNH | SLDSCILCTV | CKEDKVVETR |
| 130 | 140 | 150 | 160 | 170 | 180 |
| CNITTNTVCR | CKPGTFEDKD | SPEICQSCSN | CTDGEEELTS | CTPRENRKCV | SKTAWASWHK |
| 190 | 200 | 210 | 220 | 230 | 240 |
| LGLWIGLLVP | VVLLIGALLV | WKTGAWRQWL | LCIKRGCERD | PESANSVHSS | LLDRQTSSTT |
| 250 | 260 | 270 | 280 | 290 | 300 |
| NDSNHNTEPG | KTQKTGKKLL | VPVNGNDSAD | DLKFIFEYCS | DIVPFDSWNR | LMRQLGLTDN |
| 310 | 320 | 330 | 340 | 350 | 360 |
| QIQMVKAETL | VTREALYQML | LKWRHQTGRS | ASINHLLDAL | EAVEERDAME | KIEDYAVKSG |
| 370 | 380 | ||||
| RFTYQNAAAQ | PETGPGGSQC | V |